SVB Leerink Maintains Outperform on AlloVir, Lowers Price Target to $30
SVB Leerink analyst Mani Foroohar maintains AlloVir (NASDAQ:ALVR) with a Outperform and lowers the price target from $32 to $30.
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours:
CORRECTION: BMO Capital Initiates Coverage On Avalara with Outperform Rating, Announces Price Target of $130 – Posted as AlloVir (NASDAQ: ALVR) on February 1, 2022
CORRECTION: BMO Capital analyst Daniel Jester initiates coverage on Avalara (NYSE:AVLR) with a Outperform rating and announces Price Target of $130. BMO has not initiated coverage of AlloVir (NASDAQ:ALVR). They
Analyst Ratings For Avalara
Over the past 3 months, 4 analysts have published their opinion on Avalara (NASDAQ: AVLR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
BMO Capital Initiates Coverage On AlloVir with Outperform Rating, Announces Price Target of $130
BMO Capital analyst Daniel Jester initiates coverage on AlloVir (NASDAQ:ALVR) with a Outperform rating and announces Price Target of $130.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.
Morgan Stanley Maintains Overweight on AlloVir, Lowers Price Target to $45
Morgan Stanley maintains AlloVir (NASDAQ:ALVR) with a Overweight and lowers the price target from $48 to $45.
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year.
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
Here's a roundup of top developments in the biotech space over the last 24 hours.